Clinical Trials
4 trialsNCT04629729 2026-03-19
FT819 in Subjects With B-cell Malignancies
Fate Therapeutics
Phase 1 Active not recruiting
NCT03677596 2023-11-22
A Study Of Two Inotuzumab Ozogamicin Doses in Relapsed/ Refractory Acute Lymphoblastic Leukemia Transplant Eligible Patients
Pfizer
Phase 4 Completed
NCT01786135 2017-10-19
A Safety Study of SGN-CD19A for B-Cell Lymphoma
Seagen Inc.
Phase 1 Completed
NCT01786096 2017-07-02
A Safety Study of SGN-CD19A for Leukemia and Lymphoma
Seagen Inc.
Phase 1 Completed